Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Maggioni, AP; Anker, SD; Dahlström, U; Filippatos, G; Ponikowski, P; Zannad, F; Amir, O; Chioncel, O; Leiro, MC; Drozdz, J; Erglis, A; Fazlibegovic, E; Fonseca, C; Fruhwald, F; Gatzov, P; Goncalvesova, E; Hassanein, M; Hradec, J; Kavoliuniene, A; Lainscak, M; Logeart, D; Merkely, B; Metra, M; Persson, H; Seferovic, P; Temizhan, A; Tousoulis, D; Tavazzi, L; Heart Failure Association of the ESC.
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry.
Eur J Heart Fail. 2013; 15(10):1173-1184 Doi: 10.1093/eurjhf/hft134 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Fruhwald Friedrich

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

To evaluate how recommendations of European guidelines regarding pharmacological and non-pharmacological treatments for heart failure (HF) are adopted in clinical practice. The ESC-HF Long-Term Registry is a prospective, observational study conducted in 211 Cardiology Centres of 21 European and Mediterranean countries, members of the European Society of Cardiology (ESC). From May 2011 to April 2013, a total of 12,440 patients were enrolled, 40.5% with acute HF and 59.5% with chronic HF. Intravenous treatments for acute HF were heterogeneously administered, irrespective of guideline recommendations. In chronic HF, with reduced EF, renin-angiotensin system (RAS) blockers, beta-blockers, and mineralocorticoid antagonists (MRAs) were used in 92.2, 92.7, and 67.0% of patients, respectively. When reasons for non-adherence were considered, the real rate of undertreatment accounted for 3.2, 2.3, and 5.4% of the cases, respectively. About 30% of patients received the target dosage of these drugs, but a documented reason for not achieving the target dosage was reported in almost two-thirds of them. The more relevant reasons for non-implantation of a device, when clinically indicated, were related to doctor uncertainties on the indication, patient refusal, or logistical/cost issues. This pan-European registry shows that, while in patients with acute HF, a large heterogeneity of treatments exists, drug treatment of chronic HF can be considered largely adherent to recommendations of current guidelines, when the reasons for non-adherence are taken into account. Observations regarding the real possibility to adhere fully to current guidelines in daily clinical practice should be seriously considered when clinical practice guidelines have to be written.
Find related publications in this database (using NLM MeSH Indexing)
Adrenergic beta-Antagonists - therapeutic use
Aged -
Ambulatory Care - standards
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Cardiology - standards
Cardiotonic Agents - therapeutic use
Defibrillators, Implantable - utilization
Diuretics - therapeutic use
Diuretics -
Female -
Guideline Adherence - statistics & numerical data
Heart Failure - therapy
Hospitalization - statistics & numerical data
Humans -
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Male -
Middle Aged -
Mineralocorticoid Receptor Antagonists - therapeutic use
Nitrates - therapeutic use
Platelet Aggregation Inhibitors - therapeutic use
Practice Guidelines as Topic -
Registries -

Find related publications in this database (Keywords)
Heart failure
ACE inhibitors
© Med Uni Graz Impressum